Skip to main content

What we learned at this year’s DayOne Conference

| News

What we learned at this year’s DayOne Conference

19.10.2019

DayOne Conference 2019

Twenty-two panellists and speakers, among them 3 patients and digital health futurist Maneesh Juneja, 30 project champions and their mentors, 40 volunteers and 450 participants and Arcondis as conference Partner  — this was the DayOne Conference which took place on September 9 at the FHNW in Muttenz.

It is fair to say that the format, now in its fourth edition, has established itself, even though change in terms of location and order of events has been and will most probably continue to be constant, given the mission of DayOne to shape the future of health. What will remain are the basic ingredients – a growing community of healthcare innovators and their appetite to share their expertise and co-create with their peers.

Representing the vibrant healthcare ecosystem of the Basel region and beyond, the DayOne innovation community is attracting ever more entrepreneurs to attend the open innovation session at the conference; the session includes both applicants to the DayOne accelerator program and also ventures and projects for which feedback is sought. This big collaborative effort makes the DayOne Conference unique, even for entrepreneurs from abroad.

Also unique to the DayOne Conference is the openness to talk about neglected issues. One of these is – strangely enough for this industry – the need to include the patient’s view. In fact, the conference started and set the tone with a patients’ panel, followed by a session on future ethics in healthcare and a session on financing innovation – beyond venture capital.

The following are our personal takeaways from this year’s DayOne Conference:

1) Patient centricity is key: Even though starting with the patients seems the most obvious in healthcare innovation, there still seems to be considerable reluctance to accept this concept. The patient stories on stage clearly showed the necessity: As technology evolves, allowing new ways for patients to monitor and more efficiently (self)manage their health states, new applications will only succeed if they bring tangible value to end-users and improve their quality of life.

2) No trust, no business: Trust in technology is becoming a crucial factor for advancing innovation. Ethics therefore matter. Patients and individuals will only share their data for a good reason and if they get something out of it. In the long run, Health Data Ecosystems, the foundation of healthcare innovation, will not thrive in an environment of unilateral enforcement and exploitation.

3) De-risking investment through collaboration: Regarding the investments flowing into Digital Health, Europe seems to be losing out between the superpowers of the east (China) and west (USA). However, money cannot buy everything. What bright minds need most of all is innovation ecosystems where their ideas can be nourished and validated, providing access to healthcare providers and industry. Thus, building on a strong collaborative effort between stakeholders will stimulate entrepreneurial appetite and de-risk investments.

4) Entrepreneurs need diversity: Technology is there and ready to use. A key differentiator for digital health start-ups is the ability to make the best use of it. This requires a culture of integrating diverse capabilities, such as data sciences, medicine, research, patient/user experience and also commercialisation. In this respect, DayOne hubs with their community approach are becoming increasingly crucial for business creation.

(This report hast been co-authored by Manuel Kammermann, Arcondis)

A huge thank you for everyone who made this year’s DayOne Conference happen!

Canton of Basel-Stadt and BaselArea.swiss for facilitating. Our Conference Partner: Arcondis. 

The Patients: Cecile Tardy, Judith Safford, Peter Loewenberg

The Speakers and Panellist on Ethics: Nicholetta Iacobacci, Exponential Ethics; Evelyne Bischof, Shanghai Jiao Tong University School of Medicine; Bram Stieltjes, Universitätsspital Basel; Daniel R. Karlin, HealthMode; Athula Herath, Novartis; Erik Schkommodau, FHNW

The Speakers and on Financing: Andreas Igel, Arcondis; Julien de Salaberry, Galen Growth; Alex Buech, Medical Insights; Jan Vichr, Canopei; Sybille Fischer, Baloise; Gabor Szinnai, UKBB; Stephanie Bova, Takeda; Amine Korchi, Fusion; André Guedel, KPMG

Keynote: Maneesh Juneja, Digital Health Futurist, London

Moderation and Curation: Thomas Brenzikofer and Doug Häggström

Open Innovation Head Coaches: Aurelie Moser, Viktor Bullain, Egle B. Thomas

30 Projects Champions, their mentors and 40 Volunteers

And to our DayOne Conference supporting partners: MedInside, Swiss Healthcare Startups, CSEM, ETH Zürich- DBSSE, FHNW, Swiss Institute of Bioinformatics, Swiss TPH, UKBB, Universität Basel, Universitätsspital Basel, ELCA, SAS, Soladis Group

See the presentations

Check out the project’s work

Background read on the Future of Health 

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Forty51 Ventures invests to found Mysthera Therapeutics

Mysthera Therapeutics AG has been founded in Basel. Forty51 Ventures, a venture capital firm also based in Basel, has provided...
Read More

Spexis receives capital commitment of 2.5 million US dollars

Investors have made an additional capital commitment to Spexis AG, based in the Basel Area. With an extra 2.5 million...
Read More

Worg secures financing of 130 million Swiss francs

The Chinese biopharmaceutical firm Worg Pharma, whose European headquarters are located in the Basel Area, has secured gross proceeds equivalent...
Read More

Tenpoint aims to make vision loss reversible

The startup Tenpoint Therapeutics has started operations with a funding round of 70 million US dollars. It works to make...
Read More

Roche and ETH training the next generation of researchers

Roche, the Basel-based life sciences firm, and the Swiss Federal Institute of Technology in Zurich (ETH) are joining forces to...
Read More

Clear Solutions Labs seeks to benefit from the Basel Area

The founders of Clear Solutions Laboratories are putting together a team of experts in the fields of biotechnology, pharmaceutical science...
Read More

QuantumBasel offers access to the world’s most powerful quantum computers

QuantumBasel has consolidated its status as a neutral quantum hub with access to the world’s best quantum computers through a...
Read More

How digital transformation is driving pharmaceutical innovation in Basel

How are digital innovations such as artificial intelligence (AI) and machine learning (ML) helping to improve drug research and development?...
Read More

Medical informatics is shaping Switzerland’s digital future

Switzerland is at the forefront of embracing medical informatics, and innovative biotech hubs – such as the Basel Area –...
Read More

Ground-breaking oncology being developed in the Basel Area

The Basel Area – covering northwestern Switzerland – has seen tremendous growth in recent years, and has become a true...
Read More

Genedata expanding its user network

The Japanese biopharmaceutical firm Ajinomoto is to use the Genedata solution to accelerate its drug development processes at its site...
Read More

How Moderna is growing in Switzerland

The number one rule in real estate is “Location, Location, Location.” The global biotech company Moderna found its location in...
Read More

Sandoz decides on Basel for headquarters

Sandoz AG will continue to have its headquarters in Basel as an independent company. The separation from Novartis is expected...
Read More

VectivBio sold for approximately 1 billion dollars

The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...
Read More

University of Basel and RocketVax present new Covid vaccine

Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...
Read More

Rami Swiss and Elbit Systems now manufacturing in Jura

The newly established company Rami Swiss has inaugurated a new production facility in Courtételle in the canton of Jura together...
Read More
1 2 3 12

Do you have a question? We'd like to hear from you.